TIAA CREF Investment Management LLC boosted its holdings in shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) by 11.8% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 37,295 shares of the company’s stock after buying an additional 3,939 shares during the quarter. TIAA CREF Investment Management LLC owned 0.14% of Voyager Therapeutics worth $334,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Bank of New York Mellon Corp raised its position in Voyager Therapeutics by 20.9% during the 2nd quarter. Bank of New York Mellon Corp now owns 53,225 shares of the company’s stock worth $477,000 after buying an additional 9,207 shares during the last quarter. Wells Fargo & Company MN raised its position in Voyager Therapeutics by 9.3% during the 2nd quarter. Wells Fargo & Company MN now owns 91,384 shares of the company’s stock worth $819,000 after buying an additional 7,807 shares during the last quarter. Hershey Trust Co. raised its position in Voyager Therapeutics by 163.0% during the 2nd quarter. Hershey Trust Co. now owns 14,394 shares of the company’s stock worth $129,000 after buying an additional 8,921 shares during the last quarter. Bessemer Group Inc. raised its position in Voyager Therapeutics by 148.1% during the 2nd quarter. Bessemer Group Inc. now owns 44,828 shares of the company’s stock worth $402,000 after buying an additional 26,763 shares during the last quarter. Finally, Russell Investments Group Ltd. raised its position in Voyager Therapeutics by 57.7% during the 2nd quarter. Russell Investments Group Ltd. now owns 11,864 shares of the company’s stock worth $106,000 after buying an additional 4,343 shares during the last quarter. 37.04% of the stock is owned by institutional investors.

Shares of Voyager Therapeutics, Inc. (NASDAQ VYGR) opened at $14.18 on Thursday. Voyager Therapeutics, Inc. has a one year low of $8.10 and a one year high of $25.99.

A number of brokerages have recently commented on VYGR. ValuEngine cut shares of Voyager Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Friday, July 28th. Stifel Nicolaus began coverage on shares of Voyager Therapeutics in a research note on Friday, July 28th. They set a “buy” rating and a $20.00 price objective on the stock. Cowen and Company reaffirmed a “buy” rating on shares of Voyager Therapeutics in a research note on Tuesday, August 8th. Zacks Investment Research cut shares of Voyager Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, August 11th. Finally, Evercore ISI began coverage on shares of Voyager Therapeutics in a research note on Wednesday, August 16th. They set an “outperform” rating and a $12.00 price objective on the stock. Three investment analysts have rated the stock with a sell rating, one has issued a hold rating and nine have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $26.13.

ILLEGAL ACTIVITY NOTICE: This piece was first published by Watch List News and is the property of of Watch List News. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of United States & international copyright law. The correct version of this piece can be read at https://www.watchlistnews.com/tiaa-cref-investment-management-llc-acquires-3939-shares-of-voyager-therapeutics-inc-vygr/1720983.html.

In other news, insider Bernard Ravina sold 5,490 shares of the firm’s stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of $10.00, for a total transaction of $54,900.00. Following the sale, the insider now owns 17,157 shares of the company’s stock, valued at approximately $171,570. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold a total of 38,430 shares of company stock worth $562,890 in the last ninety days. Corporate insiders own 8.00% of the company’s stock.

Voyager Therapeutics Profile

Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s pipeline consists of programs for CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington’s disease; Friedreich’s ataxia; frontotemporal dementia/Alzheimer’s disease, and severe chronic pain.

Institutional Ownership by Quarter for Voyager Therapeutics (NASDAQ:VYGR)

Receive News & Ratings for Voyager Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.